ReviewOncotarget2017
Tumor reductive therapies and antitumor immunity.
Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 17 citations in OpenAlex.
- Redox-Responsive Drug Delivery Systems: A Chemical Perspective.Nanomaterials (Basel, Switzerland) · 2022Review
- Ultrasound Triggers Hypericin Activation Leading to Multifaceted Anticancer Activity.Pharmaceutics · 2022Article
- Radiation-induced bystander and abscopal effects: important lessons from preclinical models.British journal of cancer · 2020Review
- Cannabidiol-from Plant to Human Body: A Promising Bioactive Molecule with Multi-Target Effects in Cancer.International journal of molecular sciences · 2019Review
- The Goldilocks Window of Personalized Chemotherapy: Getting the Immune Response Just Right.Cancer research · 2019Article
- Immunomodulatory Changes Following Isolated RF Ablation in Colorectal Liver Metastases: A Case Report.Medicines (Basel, Switzerland) · 2019Article
- Mechanisms and immunogenicity of nsPEF-induced cell death in B16F10 melanoma tumors.Scientific reports · 2019Article
- The role of macrophages in the differentiation process of ureteral polyps.The Journal of international medical research · 2018Article
- A Novel Three-Dimensional Immune Oncology Model for High-Throughput Testing of Tumoricidal Activity.Frontiers in immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor reductive therapy is to reduce tumor burden through direct killing of tumor cells. So far, there is no report on the connection between antitumor immunity and tumor reductive therapies. In the last few years, a new category of cancer treatment, immunotherapy, emerged and they are categorized separately from classic cytotoxic treatments (chemo and radiation therapy). The most prominent examples include cellular therapies (LAK and CAR-T) and immune checkpoint inhibitors (anti-PD-1 and CTLA-4). Recent advances in clinical immunotherapy and our understanding of the mechanism behind them revealed that these therapies have a closer relationship with classic cancer treatments than we thought. In many cases, the effectiveness of classic therapies is heavily influenced by the status of the underlying antitumor-immunity. On the other hand, immunotherapies have shown better outcome when combined with tumor reductive therapies, not only due to the combined effects of tumor killing by each therapy but also because of a synergy between the two. Many clinical observations can be explained once we start to look at these classic therapies from an immunity standpoint. We have seen their direct effect on tumor antigen
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.